| Literature DB >> 35173439 |
Tanja A Stamm1,2, Yuki Seidler1, Margaret R Andrews1, Mohammad Eghbali3, Juliet Kiguli4, Valentin Ritschl1, Maisa Omara1,2, Gertraud Schaffer5, Erika Mosor1.
Abstract
OBJECTIVE: Several comments and recommendations called to embed better the patients' and public voice in healthcare policymaking. Still, no studies captured patients' bottom-up perspectives regarding healthcare at the time of COVID-19 at a micro-level in a range of different countries. We, therefore, explored the perspectives of patient representatives in all six World Health Organisation (WHO) regions and extracted suggestions for care redesign after the pandemic.Entities:
Keywords: COVID-19; SARS CoV-2; co-creation; coronavirus; equity; patient perspectives
Year: 2022 PMID: 35173439 PMCID: PMC8842642 DOI: 10.2147/JMDH.S341010
Source DB: PubMed Journal: J Multidiscip Healthc ISSN: 1178-2390
Characteristics of the Patient Representatives
| No | Age Group (Years) | Years Working as a Representative | Sex | Country | Type of Patient Organisation/Disease Area | Is a Patient Her/Himself |
|---|---|---|---|---|---|---|
| 1 | 40–49 | 14 | Female | Argentina | Diseases of the musculoskeletal system and connective tissue | |
| 2 | 60–69 | 36 | Male | Australia | Certain infectious and parasitic diseases | x |
| 3 | 40–49 | 0.4 | Female | Australia | Neoplasms | x |
| 4 | 60–69 | 26 | Female | Austria | Diseases of the musculoskeletal system and connective tissue | x |
| 5 | 50–59 | 34 | Female | Austria | Diseases of the musculoskeletal system and connective tissue | x |
| 6 | 40–49 | 16 | Female | Austria | Frailty and cognitive impairment due to ageing | |
| 7 | 40–49 | 21 | Female | Austria | Diseases of the digestive system | x |
| 8 | 30–39 | 6 | Female | Austria | Diseases of the musculoskeletal system and connective tissue | x |
| 9 | 50–59 | 10 | Male | Azerbaijan | Chronic disease, general | |
| 10 | 60–69 | 20 | Female | Canada | Diseases of the musculoskeletal system and connective tissue | x |
| 11 | 60–69 | 7 | Female | Canada | Diseases of the musculoskeletal system and connective tissue | x |
| 12 | 60–69 | 25 | Male | China | Chronic disease, general | |
| 13 | 50–59 | 12 | Female | Cyprus | Diseases of the musculoskeletal system and connective tissue | x |
| 14 | 50–59 | 20 | Female | Denmark | Diseases of the musculoskeletal system and connective tissue | x |
| 15 | 20–29 | 8 | Male | Egypt | Certain infectious and parasitic diseases | |
| 16 | 60–69 | 31 | Male | Germany | Diseases of the musculoskeletal system and connective tissue | x |
| 17 | 60–69 | 27 | Female | India | Neoplasms | x |
| 18 | 30–39 | 5 | Male | Iran | Endocrine, nutritional and metabolic diseases | |
| 19 | 50–59 | 5 | Female | Israel | Diseases of the musculoskeletal system and connective tissue | x |
| 20 | 50–59 | 8 | Female | Italy | Diseases of the musculoskeletal system and connective tissue | x |
| 21 | 40–49 | 25 | Female | Italy | Diseases of the musculoskeletal system and connective tissue | x |
| 22 | 50–59 | 20 | Male | Japan | Diseases of the musculoskeletal system and connective tissue | x |
| 23 | 50_59 | 9 | Female | Japan | Frailty and cognitive impairment due to ageing | |
| 24 | 70–79 | 16 | Male | Mexico | Neoplasms | |
| 25 | 50–59 | 13 | Female | Portugal | Diseases of the musculoskeletal system and connective tissue | x |
| 26 | 40–49 | 12 | Male | Russia | Certain infectious and parasitic diseases | |
| 27 | 40–49 | 15 | Female | Senegal | Certain infectious and parasitic diseases | |
| 28 | 50–59 | 20 | Female | Senegal | Certain infectious and parasitic diseases | |
| 29 | 50–59 | 28 | Female | S. Africa | Diseases of the musculoskeletal system and connective tissue | |
| 30 | 50–59 | 24 | Female | Uganda | Endocrine, nutritional and metabolic diseases | |
| 31 | 20–29 | 8 | Male | UK | Diseases of the musculoskeletal system and connective tissue | x |
| 32 | 50–59 | 13 | Female | UK | Diseases of the musculoskeletal system and connective tissue | |
| 33 | 40–49 | 4 | Female | Ukraine | Certain infectious and parasitic diseases | x |
| 34 | 30–39 | 10 | Female | USA | Neoplasms | x |
Main Themes and Related Codes
| Main Themes | Codes | No.* |
|---|---|---|
| Theme 1: Increasing inequity in the context of care | Overload of the health system | 1 |
| Reduced care and support | 2 | |
| Test accessibility/affordability/availability/frequency/necessity | 3–7 | |
| Restrictions accommodation and transportation | 8–9 | |
| Fear of getting COVID-19/ infecting others/side effect medication/suboptimal care | 10–11, 13–14 | |
| Fear (and real) drug shortages | 12 | |
| Loneliness and mental health | 15 | |
| Managing chronic disease in times of COVID-19 | 16 | |
| Reduced physical functions | 17 | |
| Reduced preventative measures | 18 | |
| Restrictions in the basic supply | 19 | |
| Increased solidarity, empathy and respect | 20 | |
| More time to manage daily life and own health/to think and reflect | 21–22 | |
| Needs for extra support | 23 | |
| Migrants/Older adults/People with dementia/People with physical disability/Rural residents/ Socio-economically-disadvantaged | 24–29 | |
| Disease stigma (other than COVID-19), discrimination and racism | 30 | |
| Violence | 31 | |
| Changes over time: Positive and negative | 59 | |
| 2. Stigma and discrimination in cultural context | Stigma, COVID-19 infection/other diseases | 32 |
| Stigma, COVID-19 testing | 33 | |
| 3. Telehealth is indispensable now and in the future, but with limitations | A learning experience | 34 |
| Creativity | 35 | |
| Positive statements (incl. opportunity) | 36 | |
| Not sufficient | 37 | |
| Technical, physical and usability barriers and accessibility | 38 | |
| 4. Patient representatives as essential connectors and influencers | Creating a safe environment/Making efforts to continue care | 39, 45 |
| Empowering communication/Having trained and competent Healthcare providers/ Healthcare providers’ communication that considers patients’ COVID-related fears/Re-assuring and honest communication | 40, 42–43, 46 | |
| Financial support continued | 41 | |
| Information from a trusted person | 44 | |
| Communicator and influencer | 47 | |
| Support to others | 48 | |
| Being challenged as representatives/advocates and reasons | 49 | |
| A reluctant influencer in vaccination | 50 | |
| Vaccination advantages include hope | 51 | |
| Vaccination availability/freedom of choice/ information needed (types of information needed)/not the ultimate solution/ uncertainty | 52–56 | |
| COVID-19 as an opportunity (other than telehealth) | 57 | |
| Understanding both sides | 58 | |
| Changes over time: positive and negative | 59 |
Notes: *Code numbers correspond to . Codebook — Codes and definitions.